A University of Otago-led study has found a highly vulnerable weakness in drug-resistant Mycobacterium tuberculosis, offering ...
Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback